Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives.
metastatic renal cell cancer
tivozanib
tyrosine kinase inhibitor
Journal
International journal of nephrology and renovascular disease
ISSN: 1178-7058
Titre abrégé: Int J Nephrol Renovasc Dis
Pays: New Zealand
ID NLM: 101550217
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
10
2018
accepted:
03
04
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with disease progression during or after cytokine therapy. Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.
Identifiants
pubmed: 31190952
doi: 10.2147/IJNRD.S169056
pii: 169056
pmc: PMC6526773
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
137-141Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Urol. 2000 Feb;163(2):408-17
pubmed: 10647643
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Cancer Res. 2006 Sep 15;66(18):9134-42
pubmed: 16982756
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Lancet. 2007 Dec 22;370(9605):2103-11
pubmed: 18156031
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Nat Rev Urol. 2010 May;7(5):245-57
pubmed: 20448658
Clin Cancer Res. 2011 Nov 15;17(22):7156-63
pubmed: 21976547
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
J Clin Oncol. 2012 May 10;30(14):1678-85
pubmed: 22493422
Cancer Sci. 2013 Aug;104(8):1039-44
pubmed: 23679664
Eur J Cancer. 2013 Sep;49(13):2841-50
pubmed: 23726267
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
J Clin Oncol. 2013 Oct 20;31(30):3791-9
pubmed: 24019545
Lancet Oncol. 2013 Dec;14(13):1287-94
pubmed: 24206640
Lancet Oncol. 2015 Mar;16(3):293-300
pubmed: 25681967
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Eur J Cancer. 2018 May;94:87-94
pubmed: 29547835
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951
pubmed: 29753637
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
Cancer. 2018 Sep 15;124(18):3677-3683
pubmed: 30307610
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497